¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cutaneous lupus erythematosus"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lupus tumidus
    ºñ´ë·çǪ½º, ºÎÀº·çǪ½º
  • lupus vulgaris
    º¸Åë·çǪ½º
  • cutaneous
    ÇǺÎ-
  • cutaneous allergy
    ÇǺξ˷¹¸£±â
  • cutaneous asthma
    ÇǺÎõ½Ä
  • cutaneous basophil hypersensitivity
    ÇǺÎÈ£¿°±¸°ú¹Î(Áõ)
  • cutaneous drug reaction
    ÇǺξ๰¹ÝÀÀ
  • cutaneous gangrene
    ÇǺα«Àú
  • cutaneous habronemiasis
    ÇǺÎÇϺê·Î³×¸¶Áõ
  • cutaneous hallucination
    ÇǺÎȯ°¢
  • cutaneous helminthiasis
    ÇǺο¬ÃæÁõ
  • cutaneous horn
    ÇǺλÔ
  • cutaneous larva migrans
    ÇǺξֹú·¹ÀÌÇàÁõ, ÇǺÎÀ¯ÃæÀÌÇàÁõ
  • cutaneous leishmaniasis
    ÇǺθ®½´¸¸Æí¸ðÃæÁõ
  • cutaneous lymphoid hyperplasia
    ÇǺθ²ÇÁ°ú´ÙÇü¼º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lupus vulgaris
    º¸Åë·çǪ½º
  • cutaneous allergy
    ÇǺξ˷¹¸£±â
  • cutaneous asthma
    ÇǺÎõ½Ä
  • passive cutaneous anaphylaxis
    ¼öµ¿ÇǺξƳªÇʶô½Ã½º
  • cutaneous
    ÇǺÎ-
  • cutaneous larva migrans
    ÇǺξֹú·¹ÀÌÇàÁõ, ÇǺÎÀ¯ÃæÀÌÇàÁõ
  • cutaneous disorder
    ÇǺÎÁúȯ
  • cutaneous endometriosis
    Ç¥ÀçÀڱ󻸷Áõ, Ç¥¸éÀڱ󻸷Áõ
  • cutaneous gangrene
    ÇǺα«Àú
  • cutaneous habronemiasis
    ÇǺÎÇϺê·Î³×¸¶Áõ
  • cutaneous hallucination
    ÇǺÎȯ°¢
  • cutaneous helminthiasis
    ÇǺο¬ÃæÁõ
  • cutaneous horn
    ÇǺλÔ
  • cutaneous leishmaniasis
    ÇǺθ®½´¸¸Æí¸ðÃæÁõ
  • cutaneous neoplasm
    ÇǺÎÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inferior lateral cutaneous nerve of arm
    ¾Æ·¡°¡ÂÊÀ§ÆÈÇǺνŰæ
  • posterior cutaneous branch
    µÚÇǺΰ¡Áö
  • posterior cutaneous nerve of arm
    µÚÀ§ÆÈÇǺνŰæ
  • posterior cutaneous nerve of forearm
    µÚ¾Æ·¡ÆÈÇǺνŰæ
  • posterior femoral cutaneous nerve
    µÚ³Ò´Ù¸®ÇǺνŰæ
  • primary cutaneous adenocystic carcinoma
    ¿ø¹ß¼º ÇǺΠ¼±³¶Á¾¼º¾Ï
  • primary localized cutaneous amyloidosis
    ¿ø¹ß¼º ±¹¼Ò ÇǺΠÀ¯ÀüºÐÁõ
  • random cutaneous flap
    ÀÓÀÇÇÇÆÇ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lupus erythematosus =LE ³ª
    È«¹Ý¼º ·çǪ½º.
  • lupus erythematosus =le ³ª
    È«¹Ý¼º ·çǪ½º(ûõÚèàõ ¡­)
  • lupus erythematosus cell
    È«¹Ý¼º³¶Ã¢¼¼Æ÷
  • lupus erythematosus cell = LE cell
    È«¹Ý¼º ·çǪ½º¼¼Æ÷(¡­á¬øà)
  • lupus erythematosus disseminatus ³ª
    ÆÄÁ¾»ó(÷ëðúßÒ)È«¹Ý¼º ·çǪ½º.
  • lupus erythematosus factor = LE factor
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­)
  • lupus erythematosus factor =LE f.
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­).
  • lupus erythematosus like syndrome
    È«¹Ý¼º ·çǪ½º¾çÁõÈıº(ûõÚèàõ¡­åÆñøý¦ÏØ )
  • lupus erythematosus phenomenon = LE phenomenon
    È«¹Ý¼º ·çǪ½ºÇö»ó(¡­úÞßÚ)
  • lupus erythematosus phenomenon =LE p.
    È«¹Ý¼º ·çǪ½ºÇö»ó(¡­úÞßÚ).
  • lupus erythematosus profundus
    ½ÉÀ缺 È«¹Ý¼º ·çǪ½º
  • lupus erythematosus test = LE test
    È«¹Ý¼º ·çǪ½º½ÃÇè(¡­ãËúÐ)
  • neonatal systemic lupus erythematosus
    ½Å»ý¾Æ Àü½Å¼º È«¹Ý¼º ·çǪ½º
  • sle= systemic lupus erythematosus
    Àü½Å¼º È«¹Ý¼º ·çǪ½º(îïãóàõ ûõÚèàõ¡­)
  • systemic lupus erythematosus
    Àü½Å¼ºÈ«¹Ý¼º·çÇÁ½º
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Medial cutaneous nerve of arm
    ¾ÈÂÊÀ§ÆÈÇǺνŰæ
    [¿¾ ¿ë¾î] ³»Ãø»ó¿ÏÇǽŰæ
  • Medial sural cutaneous nerve
    ¾ÈÂÊÀåµýÁöÇǺνŰæ
    [¿¾ ¿ë¾î] ³»Ãøºñº¹ÇǽŰæ
  • Medial cutaneous branches of leg
    ¾ÈÂÊÁ¾¾Æ¸®ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ³»ÃøÇÏÅðÇÇÁö
  • Medial cutaneous branch
    ¾ÈÂÊÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ³»ÃøÇÇÁö
  • Anterior cutaneous branch (of thorax)
    ¾Õ(°¡½¿)ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] Àü(Èä)ÇÇÁö
  • Anterior cutaneous branch (of abdomen)
    ¾Õ(¹è)ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] Àü(º¹)ÇÇÁö
  • Anterior cutaneous branch
    ¾ÕÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ÀüÇÇÁö
  • Anterior cutaneous branches
    ¾ÕÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ÀüÇÇÁö
  • Superior lateral cutaneous nerve of arm
    À§°¡ÂÊÀ§ÆÈÇǺνŰæ
    [¿¾ ¿ë¾î] »ó¿ÜÃø»ó¿ÏÇǽŰæ
  • Intermediate dorsal cutaneous nerve
    Áß°£¹ßµîÇǺνŰæ
    [¿¾ ¿ë¾î] ÁßÁ·¹èÇǽŰæ
  • Cutaneous branch
    ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ÇÇÁö
  • Cutaneous branches
    ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ÇÇÁö
  • Cutaneous sulci
    ÇǺΰí¶û
    [¿¾ ¿ë¾î] ÇǺμұ¸
  • Cutaneous muscle
    ÇǺαÙÀ°
    [¿¾ ¿ë¾î] ÇDZÙ
  • Cutaneous ridges
    ÇǺδɼ±
    [¿¾ ¿ë¾î] ÇǺμҸª
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SLE Systemic Lupus Erythematosus; Àü½Å¼º È«¹Ý¼º ·çǪ½º(³¶Ã¢)(îïãóàõ ûõÚèàõ)
CDLE chronic discoid lupus erythematosus
DIL, Dil Dilantin; drug-induced lupus [erythematosus]
DILE drug-induced lupus erythematosus
LE lactate extraction; left ear; left eye; leukocyte elastase; leukoerythrogenic; live embryo; Long Eva...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SLEDAI Systemic Lupus Erythematosus Disease Activity Index
BILAG British Isles Lupus Assessment Group
DPLN Diffuse proliferative lupus nephritis
LAC Lupus AntiCoagulant
LA lupus anticoagulans
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lupus vulagris
    ½É»ó¼º ³¶Ã¢, ½É»ó¼º ·çǪ½º, º¸Åë ·çǪ½º
    ÇǺÎÀÇ ¿ø¹ß¼º °áÇÙÀ¸·Î ±«¾ç¼ºÀÇ ±¸Áø¼º ¼Ò°áÀýÀ» º¸ÀÌ¸ç Æ¯È÷ ¾ó±¼¿¡ Àß ¹ß»ýÇÑ´Ù.
  • lupus-like syndrome
    ³¶Ã¢ ¾ç»óÀÇ ÁõÈıº
  • American cutaneous Leishmaniasis
    ¾Æ¸Þ¸®Ä« ÇǺΠ¸®½´¸¶´Ï¾Æº´
  • anterior cutaneous branch of abdomen
    ¾Õ¹è ÇǺΰ¡Áö
  • chronic infantile neurological cutaneous articular syndrome
    ¸¸¼º À¯¾Æ ½Å°æ ÇǺαº
  • cutaneous afferent
    ÇǺΠ±¸½É ½Å°æ
  • cutaneous artery
    ÇǺΠµ¿¸Æ
  • cutaneous B cell lymphoma
    ÇǺΠB ¼¼Æ÷ ¸²ÇÁÁ¾
  • cutaneous burn
    ÇǺΠȭ»ó
  • cutaneous circulation
    ÇǺΠ¼øÈ¯
  • cutaneous gland
    ÇǺΠ¼±
  • cutaneous hyperactivity
    ÇǺΠ°ú¹Î ¹ÝÀÀ
  • cutaneous hypersensitivity
    ÇǺΠ°ú¹ÎÁõ
  • cutaneous lymphoblastoma
    ÇǺΠ¸²ÇÁ¾Æ¼¼Æ÷Á¾
  • cutaneous manifestation
    ÇǺΠÁõ»ó ¹× ¡ÈÄ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
chilblain lupus Skin lesions seen in patients with lupus erythematosus, resembling the small, hardened nodular areas of a cold injury called chilblains.
Synonym: chilblain lupus.
(05 Mar 2000)
neonatal lupus Lupus erythematosus occurring in newborn children of mothers who had lupus during pregnancy; anti-SSA antibodies usually should be screened for; 50% have anti-nuclear antibodies. A variety of skin lesions are seen, which can resolve or leave scarring; the syndrome usually resolves; however cardiac manifestations can be fatal. Some children develop systemic lupus later in life.
(05 Mar 2000)
drug-induced lupus <dermatology> An inflammatory autoimmune disorder, similar to lupus, that develops in response to the use of a particular medication. It is characterised by anti-histone antibodies. More benign than the usual disease, with less renal involvement. The syndrome clears after stopping the offending drug.
Drugs that are known to cause this reaction include procainamide, isoniazid, sulphasalazine, hydralazine, methyldopa, phenytoin, chlorpromazine and penicillamine.
The arthritis, cardiac, pulmonary and systemic features may be present, but the kidney involvement (nephritis) and neurologic disease are rare.
Symptoms generally resolve spontaneously after stopping the medication. Complications include myocarditis, pericarditis, thrombocytopenic purpura and infections.
(18 Jul 2002)
lupus A systemic disease that results from an autoimmune mechanism. Individuals with lupus will produce antibodies to their own body tissues. The resultant inflammation can cause kidney damage, arthritis, pericarditis and vasculitis.
(27 Sep 1997)
lupus anticoagulant An immunoglobulin that interferes with blood coagulation and has antithromboplastin activity. This immunoglobulin can prolong blood clotting and occurs in approximately 25% of people with lupus.
(27 Sep 1997)
lupus anticoagulants Lupus anticoagulants are a common cause of a prolonged activated partial thromboplastin time (APTT) which is corrected by the addition of platelet -rich plasma (or phospholipids) and not by platelet-poor plasma. The methods of choice for detection of lupus anticoagulants are the kaolin clotting time using the rabbit brain neutralisation procedure and the dilute Russell viper venom test (dRVVT).
Current data suggest that lupus anticoagulants and antibodies to negatively charged phospholipids (cardiolipin, phosphatidylserine, phosphatidic acid and phosphatidylinositol) are risk factors for arterial and venous thrombosis and for recurrent abortions in populations of patients which are distinct but overlapping. Drug-induced lupus anticoagulants are also associated with increased risk of thrombosis. Current testing for lupus anticoagulants and phospholipid antibodies (cardiolipin plus phosphatidylserine) may be useful for assessing risk in patients with systemic lupus erythematosus. Some data indicate that lupus anticoagulants assays are more reliable predictors of thrombosis, foetal loss and thrombocytopenia than are cardiolipin antibody (ACA) assays. Although the technology is in many ways more reliable, the rush to describe associations of lupus anticoagulants with various disorders has been much less scientifically unseemly than has been that of ACAs with their bewildering variety of clinical associations. The contribution of one serious study must, it seems, render tolerable the excess of trivia recently published in this area.
See also cardiolipin antibodies and phospholipid antibodies.
(05 Mar 2000)
lupus band test A direct immunofluorescent technique for demonstrating a band of immunoglobulins at the dermal-epidermal junction of the skin of patients with lupus erythematosus.
(05 Mar 2000)
lupus coagulation inhibitor An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications.
(12 Dec 1998)
lupus erythematodes Skin disease in which there are red scaly patches, especially over the nose and cheeks. May be a symptom of systemic lupus erythematosus.
(18 Nov 1997)
lupus glomerulonephritis-pathology Patient survival and preservation of renal function are predictable from renal pathology as demonstrated by biopsy and defined by the histological classification of the International Study of Kidney Disease in Children/World Health Organization (ISKDC/WHO). Semi-quantitative indices of nephron loss (chronicity index) and activity of acute potentially reversible inflammation (activity index) are not predictive of individual outcome, renal failure or death in patients with aggressively treated SLE GN.
(05 Mar 2000)
lupus-like syndrome <syndrome> A clinical syndrome resembling that of systemic lupus erythematosus, but due to some other cause.
(05 Mar 2000)
lupus livido Persistent cyanotic lesions on the extremities, associated with the cutaneous manifestations of Raynaud's disease.
(05 Mar 2000)
lupus lymphaticus A congenital nevoid lesion consisting of a circumscribed group of tense lymph vesicles.
Synonym: lupus lymphaticus, lymphangiectodes, lymphangioma capillare varicosum, lymphangioma superficium simplex.
(05 Mar 2000)
lupus miliaris disseminatus faciei A millet-like papular eruption of the face, associated with a (histopathologically) tuberculoid perifollicular infiltration, but probably related to rosacea rather than tuberculous infection.
(05 Mar 2000)
lupus mutilans Cutaneous tuberculosis with extensive destruction of tissue.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á